Gilead Sciences clears hurdle for pill to prevent HIV

A panel of government advisers agreed that the drug Truvada should be sold to help protect people at high risk of being infected.

By Minyanville May 11, 2012 7:37PM
Gilead Sciences (GILD) cleared a hurdle Thursday as it seeks to market its top-selling HIV drug Truvada to help prevent infection of the virus. If approved for that use, Truvada would be the first drug sold to actually help reduce the risk of HIV.

A panel of Food and Drug Administration advisers were in favor of approval of the new use for individuals at the highest risk of becoming infected. The panel was overly supportive of approving the drug for men who have sex with other men and for partners in couples in which one person is infected with HIV. The panelists were split on whether other individuals should be prescribed the drug. The FDA, which will consider the advisers’ recommendations, is scheduled to make a decision on the new use of Truvada by June 15.

While investors expect hepatitis C treatments will be a big part of Gilead's future, the company can't take its eye off its biggest business. Gilead is the dominant player for HIV drug sales and it's important for the company to keep momentum as other companies test new treatments.

Gilead scored another victory Friday, when a separate FDA panel recommended a single pill that combines four medicines for HIV-infected patients. That drug, known as Quad, may be particularly important to Gilead's HIV program.

Truvada was approved by the FDA in 2004 to treat HIV infections. Sales of the drug rose 8% to about $2.9 billion last year.

Shares of the company rose more than 1% Friday to close at $51.84.

More from Minyanville
Tags: GILD
0Comments

DATA PROVIDERS

Copyright © 2014 Microsoft. All rights reserved.

Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.

STOCK SCOUTER

StockScouter rates stocks from 1 to 10, with 10 being the best, using a system of advanced mathematics to determine a stock's expected risk and return. Ratings are displayed on a bell curve, meaning there will be fewer ratings of 1 and 10 and far more of 4 through 7.

129
129 rated 1
281
281 rated 2
444
444 rated 3
732
732 rated 4
629
629 rated 5
623
623 rated 6
610
610 rated 7
440
440 rated 8
303
303 rated 9
126
126 rated 10
12345678910

Top Picks

SYMBOLNAMERATING
BBBYBED BATH & BEYOND INC10
TWXTIME WARNER Inc10
COPCONOCOPHILLIPS9
HDHOME DEPOT Inc9
VZVERIZON COMMUNICATIONS9
More

VIDEO ON MSN MONEY

ABOUT

Top Stocks provides analysis about the most noteworthy stocks in the market each day, combining some of the best content from around the MSN Money site and the rest of the Web.

Contributors include professional investors and journalists affiliated with MSN Money.

Follow us on Twitter @topstocksmsn.